Comparative Pharmacology
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus SERENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOLINDONE HYDROCHLORIDE versus SERENTIL.
MOLINDONE HYDROCHLORIDE vs SERENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist; also blocks serotonin 5-HT2A receptors and alpha-adrenergic receptors.
SERENTIL (mesoridazine) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminic effects. It has high affinity for D2, 5-HT2A, and alpha-1 receptors.
50-225 mg/day orally in 3-4 divided doses; usual effective dose 50-75 mg/day; maximum 225 mg/day.
Oral: 50–100 mg 3 times daily; maximum 400 mg/day. IM: 25 mg every 4–6 hours.
None Documented
None Documented
1.5-2 hours; shorter than typical antipsychotics, requiring multiple daily dosing.
Terminal elimination half-life is approximately 24-30 hours in adults. Does not correlate well with duration of antipsychotic effect due to active metabolite formation.
Renal: 65-70% as metabolites and unchanged drug; Fecal: 20-25%; Biliary: minor.
Primarily renal (70-80% as conjugated and unconjugated metabolites) and fecal (15-20%). Biliary excretion contributes to enterohepatic circulation.
Category C
Category C
Antipsychotic
Antipsychotic